Sanofi has proposed to publicly acknowledge the effectiveness of a rival flu vaccine, addressing EU antitrust concerns. The ...

“Self-amplifying mRNA technology has the potential to be an enduring vaccine option," said Nobel laureate Dr. Drew Weissman, "I look forward to seeing this next generation mRNA technology protect many ...

The EU is asking for feedback on measures proposed by Sanofi to address concerns about a marketing campaign for a flu vaccine ...

Summit-based Seqirus is ramping up its fight against influenza with the completion of a $156 million expansion of its manufacturing facility in North Carolina. The influenza-focused vaccine company ...

The European Commission has kicked off formal proceedings in an antitrust investigation against Sanofi. The probe surrounds ...

CSL Seqirus, one of the world’s top flu vaccine companies, scored a $30.1 million deal from the Biomedical Advanced Research and Development Authority (BARDA) to deliver an avian flu vaccine candidate ...

For many businesses, "company culture" is today's trendy phrase, with little substance to back it up. At CSL Seqirus, however, a patient-focused company culture has become a guiding force from the CEO ...

SUMMIT, N.J., Sept. 21, 2020 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) that demonstrated an MF59® adjuvanted, ...

CSL Seqirus, a global company specialzing in the protection of public health, confirmed it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season, based on the ...

Doses of vaccine in the packaging system. Spare a bit of sympathy for our flu vaccine makers. Chris Larkins, SVP of Global Operations at Seqirus. “For flu, chasing variants is such a challenge in ...

SUMMIT, N.J., March 5, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX ® QUADRIVALENT ...